This segment focuses on the development, manufacturing, and commercialization of diagnostic tests and therapeutic solutions for gastrointestinal (GI) diseases and food intolerances. Research and development efforts are centered on the inFoods technology, an IBS therapy and diagnostic-guided therapy, and the development of diagnostic products for Helicobacter pylori. Technologies used include ELISA-based assays and potentially AI-driven analysis for predicting food sensitivities. The therapeutic areas covered include Irritable Bowel Syndrome (IBS), GERD, Crohn's Disease, and Ulcerative Colitis. The patient impact is significant, offering improved diagnosis and management of GI conditions, leading to better patient outcomes and quality of life. Biomerica's market positioning is strengthened by its focus on innovative solutions for unmet needs in GI health. Future opportunities include expanding the inFoods platform and developing new diagnostic tests. Regulatory and clinical aspects involve obtaining FDA clearance and conducting clinical trials to validate product efficacy. Partnerships and collaborations are pursued to enhance distribution and market reach, as seen with the recent distribution agreement in the UAE.

This segment concentrates on the development, manufacturing, and marketing of diagnostic test kits for diabetes and other esoteric tests. Research and development activities include the continuous improvement and expansion of existing product lines, as well as the exploration of new diagnostic markers and technologies. The company utilizes ELISA and other immunoassay technologies to measure specific substances in blood, urine, or fecal samples. Therapeutic areas include diabetes management and the diagnosis of various diseases and medical complications. The patient impact is improved through early and accurate diagnosis, enabling timely intervention and better disease management. Biomerica's market position is enhanced by its focus on providing reliable and accurate diagnostic tools for physicians' offices, over-the-counter drugstores, and hospital/clinical laboratories. Future opportunities include expanding the product portfolio and exploring new diagnostic applications. Regulatory and clinical aspects involve obtaining necessary approvals and adhering to quality standards. The company may collaborate with healthcare providers and laboratories to ensure product adoption and effective use.

This segment focuses on the development, testing, validation, and sale of diagnostic products for COVID-19 infection. Research and development activities include the continuous improvement and expansion of existing product lines, as well as the exploration of new diagnostic markers and technologies. The company utilizes ELISA and other immunoassay technologies to measure specific substances in blood, urine, or fecal samples. Therapeutic areas include COVID-19 detection and diagnosis. The patient impact is improved through early and accurate diagnosis, enabling timely intervention and better disease management. Biomerica's market position is enhanced by its focus on providing reliable and accurate diagnostic tools for physicians' offices, over-the-counter drugstores, and hospital/clinical laboratories. Future opportunities include expanding the product portfolio and exploring new diagnostic applications. Regulatory and clinical aspects involve obtaining necessary approvals and adhering to quality standards. The company may collaborate with healthcare providers and laboratories to ensure product adoption and effective use.